Cargando…

Multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy

The tumor immune microenvironment (TIME) has been demonstrated to be the main cause of cancer immunotherapy failure in various malignant tumors, due to poor immunogenicity and existence of immunosuppressive factors. Thus, establishing effective treatments for hostile TIME remodeling has considerable...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Linnan, Li, Feng, Cao, Yongsheng, Liu, Qiang, Jing, Guoxin, Niu, Jintong, Sun, Feiyue, Qian, Yechang, Wang, Shilong, Li, Ang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524820/
https://www.ncbi.nlm.nih.gov/pubmed/34663354
http://dx.doi.org/10.1186/s12951-021-01073-2
_version_ 1784585552009363456
author Yang, Linnan
Li, Feng
Cao, Yongsheng
Liu, Qiang
Jing, Guoxin
Niu, Jintong
Sun, Feiyue
Qian, Yechang
Wang, Shilong
Li, Ang
author_facet Yang, Linnan
Li, Feng
Cao, Yongsheng
Liu, Qiang
Jing, Guoxin
Niu, Jintong
Sun, Feiyue
Qian, Yechang
Wang, Shilong
Li, Ang
author_sort Yang, Linnan
collection PubMed
description The tumor immune microenvironment (TIME) has been demonstrated to be the main cause of cancer immunotherapy failure in various malignant tumors, due to poor immunogenicity and existence of immunosuppressive factors. Thus, establishing effective treatments for hostile TIME remodeling has considerable potential to enhance immune response rates for durable tumor growth retardation. This study aims to develop a novel nanocomposite, polyethyleneimine-modified dendritic mesoporous silica nanoparticles loaded with microRNA-125a (DMSN-PEI@125a) to synergistically enhance immune response and immunosuppression reversion, ultimately generating a tumoricidal environment. Our results showed that DMSN-PEI@125a exhibited excellent ability in cellular uptake by murine macrophages and the cervical cancer cell line TC-1, repolarization of tumor associated macrophages (TAMs) to M1 type in a synergistic manner, and promotion of TC-1 immunogenic death. Intratumor injection of DMSN-PEI@125a facilitated the release of more damage-related molecular patterns and enhanced the infiltration of natural killer and CD8(+) T cells. Meanwhile, repolarized TAMs could function as a helper to promote antitumor immunity, thus inhibiting tumor growth in TC-1 mouse models in a collaborative manner. Collectively, this work highlights the multifunctional roles of DMSN-PEI@125a in generating an inflammatory TIME and provoking antitumor immunity, which may serve as a potential agent for cancer immunotherapy. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-01073-2.
format Online
Article
Text
id pubmed-8524820
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85248202021-10-22 Multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy Yang, Linnan Li, Feng Cao, Yongsheng Liu, Qiang Jing, Guoxin Niu, Jintong Sun, Feiyue Qian, Yechang Wang, Shilong Li, Ang J Nanobiotechnology Research The tumor immune microenvironment (TIME) has been demonstrated to be the main cause of cancer immunotherapy failure in various malignant tumors, due to poor immunogenicity and existence of immunosuppressive factors. Thus, establishing effective treatments for hostile TIME remodeling has considerable potential to enhance immune response rates for durable tumor growth retardation. This study aims to develop a novel nanocomposite, polyethyleneimine-modified dendritic mesoporous silica nanoparticles loaded with microRNA-125a (DMSN-PEI@125a) to synergistically enhance immune response and immunosuppression reversion, ultimately generating a tumoricidal environment. Our results showed that DMSN-PEI@125a exhibited excellent ability in cellular uptake by murine macrophages and the cervical cancer cell line TC-1, repolarization of tumor associated macrophages (TAMs) to M1 type in a synergistic manner, and promotion of TC-1 immunogenic death. Intratumor injection of DMSN-PEI@125a facilitated the release of more damage-related molecular patterns and enhanced the infiltration of natural killer and CD8(+) T cells. Meanwhile, repolarized TAMs could function as a helper to promote antitumor immunity, thus inhibiting tumor growth in TC-1 mouse models in a collaborative manner. Collectively, this work highlights the multifunctional roles of DMSN-PEI@125a in generating an inflammatory TIME and provoking antitumor immunity, which may serve as a potential agent for cancer immunotherapy. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-01073-2. BioMed Central 2021-10-18 /pmc/articles/PMC8524820/ /pubmed/34663354 http://dx.doi.org/10.1186/s12951-021-01073-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yang, Linnan
Li, Feng
Cao, Yongsheng
Liu, Qiang
Jing, Guoxin
Niu, Jintong
Sun, Feiyue
Qian, Yechang
Wang, Shilong
Li, Ang
Multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy
title Multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy
title_full Multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy
title_fullStr Multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy
title_full_unstemmed Multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy
title_short Multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy
title_sort multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524820/
https://www.ncbi.nlm.nih.gov/pubmed/34663354
http://dx.doi.org/10.1186/s12951-021-01073-2
work_keys_str_mv AT yanglinnan multifunctionalsilicananocompositesprimetumoricidalimmunityforefficientcancerimmunotherapy
AT lifeng multifunctionalsilicananocompositesprimetumoricidalimmunityforefficientcancerimmunotherapy
AT caoyongsheng multifunctionalsilicananocompositesprimetumoricidalimmunityforefficientcancerimmunotherapy
AT liuqiang multifunctionalsilicananocompositesprimetumoricidalimmunityforefficientcancerimmunotherapy
AT jingguoxin multifunctionalsilicananocompositesprimetumoricidalimmunityforefficientcancerimmunotherapy
AT niujintong multifunctionalsilicananocompositesprimetumoricidalimmunityforefficientcancerimmunotherapy
AT sunfeiyue multifunctionalsilicananocompositesprimetumoricidalimmunityforefficientcancerimmunotherapy
AT qianyechang multifunctionalsilicananocompositesprimetumoricidalimmunityforefficientcancerimmunotherapy
AT wangshilong multifunctionalsilicananocompositesprimetumoricidalimmunityforefficientcancerimmunotherapy
AT liang multifunctionalsilicananocompositesprimetumoricidalimmunityforefficientcancerimmunotherapy